Therapeutic effect of the P2Y14R activation on CNS diseases are not fully elucidated yet. The P2Y14R is activated by UDP-glucose (EC50 = 80 nM).221 This endogenous ligand is not prone to hydrolysis and acts as an extracellular pro-inflammatory mediators.315 UDP also acts as a P2Y14 R agonist, overlapping with the P2Y6R. Several analogs of UDP including MRS2802 and MRS2905 have exhibited high potency and selectivity at the P2Y14 over the P2Y6 and other P2Y receptors.316 Releases of nucleotide-sugars in astrocytes play an important role in maintaining the normal status of the cell via P2Y14 receptors.317
